Morningstar[®] Document Research[™]

FORMSC 13G/A

CardioGenics Holdings Inc. - CGNH

Filed: February 14, 2014 (period:)

Amendment to the SC 13G filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 3)*

CardioGenics Holdings Inc. (Name of Issuer)

Common Stock, par value \$0.00001 per share

(Title of Class of Securities)

14160X203

(CUSIP Number)

December 31, 2013

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages Page 1 of 5 Pages

Source: CardioGenics Holdings Inc., SC 13G/A, February 14, 2014

Powered by Morningstar[®] Document Research[™]

The information contained herein may not be copied, adapted or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising from any use of this information, except to the extent such damages or losses cannot be limited or excluded by applicable law. Past financial performance is no guarantee of future results.

SCHEDULE 13G

CUSIP No.: 14160X203

Page 2 of 5 Pages

1.	Names of Reporting Persons.						
	PAUL H. SAUNDERS						
2.	Check the Appropriate Box if a Member of a Group						
	(a) []						
	(b) []						
3.	SEC Use On	ly					
4.	Citizenship or Place of Organization						
	United States of America						
Number of Shares		5.	Sole Voting Power	5,850,000			
Beneficially Owned by H Reporting		6.	Shared Voting Power	None			
Person With	1	7.	Sole Dispositive Power	5,850,000			
		8.	Shared Dispositive Power	None			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person						
	5,850,000						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)						
11.	Percent of Class Represented by Amount in Row (9)						
	9.8%						
12.	Type of Reporting Person:						
	IN						

Source: CardioGenics Holdings Inc., SC 13G/A, February 14, 2014

Powered by Morningstar $^{\ensuremath{\text{\tiny B}}}$ Document Research $^{\ensuremath{\text{\tiny SM}}}$

Item 1(a). Name of Issuer:

CardioGenics Holdings Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

6295 Northam Drive, Unit 8, Mississauga, Ontario L4V 1WB

Item 2(a). Name of Person Filing:

This Statement is filed on behalf of Paul H. Saunders ("Mr. Saunders").

Item 2(b). Address of Principal Business Office or, If None, Residence:

The address of the principal business office of Mr. Saunders is 2700 North Ocean Drive, 9A, Singer Island, Florida 33404.

Item 2(c). Citizenship:

Mr. Saunders is a citizen of the United States of America.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.00001 per share (the "Shares").

Item 2(e).	CUSIP Number:			
	14160X203			
Item 3.	If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:			
This Item 3 is r	not applicable.			

Item 4. Ownership:

Item 4(a) Amount Beneficially Owned:

As of December 31, 2013, Mr. Saunders may be deemed the beneficial owner of 5,850,000 Shares. This includes 5,400,000 Shares plus an additional 450,000 Shares which may be obtained upon exercise of 450,000 warrants.

Item 4(b) Percent of Class:

As of December 31, 2013, Mr. Saunders may be deemed the beneficial owner of approximately 9.8% of Shares outstanding. (Based upon information provided by the Issuer, there were 59,103,595 Shares deemed outstanding as of December 31, 2013. Mr. Saunders may be deemed to be the beneficial owner of 450,000 Shares upon exercise of his warrants. Pursuant to Rule 13d-3(d)(1)(i)(D), in calculating the percentage of beneficial ownership, such Shares have been added to the Issuer's number of Shares outstanding, for a total of 59,553,595 Shares outstanding.)

Powered by Morningstar[®] Document Research[™]

Item 4(c) Number of Shares of which such person has:

item i(c)	Number of Shares of which such person has.				
 (i) Sole power to vote or direct the vote: (ii) Shared power to vote or direct the vote: (iii) Sole power to dispose or direct the disposition of: (iv) Shared power to dispose or direct the disposition of: 					
Item 5.	Ownership of Five Percent or Less of a Class:				
	This Item 5 is not applicable.				
Item 6.	Ownership of More than Five Percent on Behalf of Another Person:				
	This Item 6 is not applicable.				
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:				
	This Item 7 is not applicable.				
Item 8.	Identification and Classification of Members of the Group:				
	This Item 8 is not applicable.				
Item 9.	Notice of Dissolution of Group:				
	This Item 9 is not applicable.				
Item 10.	Certification:				

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

/s/ Paul H. Saunders Paul H. Saunders

February 14, 2014

Attention: Intentional misstatements or omissions of fact constitute federal violations (see 18 U.S.C. 1001).

Source: CardioGenics Holdings Inc., SC 13G/A, February 14, 2014

Powered by Morningstar® Document ResearchSM